Skip to content Skip to sidebar Skip to footer
ASX stocks dealing with major backlashes
Here are 5 ASX stocks dealing with major backlashes from the public! Who will prevail in the tug of war?
This article outlines 5 ASX stocks dealing with major backlashes from the public. Note: We are not necessarily talking about companies facing backlash just from investors, like Droneshield is. We are talking about companies facing a backlash from the broader public. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914"…
PhosCo investors
5 Key milestones that PhosCo investors have to look forward to in 2026!
PhosCo investors have had a positive start to 2026 with the most recent assay results from its Gasaat project giving hope that there is a bright future. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] Good results at KM PhosCo received assay results from one particular prospect, the…
James Hardie (ASX:JHX): They say when things are glum there’s worse to come, but here’s why shares are bucking the trend in 2026
James Hardie (ASX:JHX) is one of the companies many would struggle to have sympathy for. It had a tortured history with its asbestos products. It was struggling even before 2025 with high inflation and subdued demand from aspirant home renovators. And then there were the events of 2025 where JHX faced the uncertainty of tariffs. And…
invest in data centre stocks
Should you invest in data centre stocks? Here are 4 reasons why you should consider, and 4 reasons why you should not
If you want to invest in data centre stocks, we would assume you are most likely thinking that it is a no-brainer as long as you have patience. You could just simply say: NextDC (ASX:NXT), alluding to that company's 100-fold growth from an $80m start-up of Bevan Slattery's to an $8bn company. You may or…
Compumedics
Compumedics (ASX:CMP): Expecting $70m sales but trading at barely over 1x Revenues, is this a buy?
Some investors may think Compumedics (ASX:CMP) is highly undervalued. It trades at $75m, a level that many clinical-stage medtech or biotech stocks are trading well above...but Compumedics is a commercial-stage company expecting nearly that amount of sales for an entire year. What's the story here? What are the Best ASX stocks to invest in right now? Check…
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here